project id: TCGA-PRAD; case submitter id: TCGA-EJ-A65J; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.88; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.43; rna integrity number: 7.9; age at index: 62; days to birth: -22904; ethnicity: not reported; gender: male; race: white; vital status: Alive; year of birth: 1950; age at diagnosis: 22904; ajcc clinical m: M0; ajcc clinical t: T3a; ajcc pathologic n: N0; ajcc pathologic t: T3a; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 451.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: yes; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 5; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 218; initial weight: 970.0; sample id: b0a9a48b-6053-469e-9812-2815bdd9aa22; sample submitter id: TCGA-EJ-A65J-01A; portion id: f25373ec-cd80-4cc5-909c-455c2e1f8089; portion submitter id: TCGA-EJ-A65J-01A-11; slide id: 8cd7beaf-a661-4944-b1b6-ba808583fde2; slide submitter id: TCGA-EJ-A65J-01A-01-TSA; percent lymphocyte infiltration: 40.0; percent monocyte infiltration: 20.0; percent necrosis: 10.0; percent neutrophil infiltration: 20.0; percent normal cells: 0.0; percent stromal cells: 10.0; percent tumor cells: 80.0; percent tumor nuclei: 80.0; section location: TOP;